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Introduction
Pseudomonas aeruginosa (P. aeruginosa) is an important opportunistic clinical pathogen, causing a variety of healthcare-associated infections, such as pneumonia, sepsis, wounds, and urinary tract infections [1, 2] . This organism is an important cause of septic mortality in burn patients [3] . P. aeruginosa is a major cause of chronic lung infections in children and young adults with cystic fibrosis and can be especially severe in neutropenic or cancer patients [4] . Infections caused by P. aeruginosa are often difficult to treat because of its intrinsic and acquired resistance to many commonly prescribed antimicrobial agents, eventually leading to the emergence of multidrug-resistant P. aeruginosa (MDR-PA) strain [5] . P. aeruginosa is physiologically resistant to many antibacterial agents, especially to the extended-spectrum cephalosporins, due to the production of different classes of extended spectrum ß-lactamases (ESBLs), overproduction of chromosomal AmpC cephalosporinase, and non-enzymatic mechanisms, such as efflux pumps and outer membrane impermeability [6] , among others. Nosocomial infections due to MDRPA strains are increasingly recognized throughout the world and are associated with increased morbidity, mortality, and cost of therapy [7, 8] . ESBLs are one of the main leading causes of resistance to ß-lactam antibiotics among Gram-negative bacteria [6] . These enzymes are plasmid-encoded β-lactamases that mediate resistance to penicillins, first-, second-and third-generation cephalosporins, such as cefotaxime, ceftriaxone, and ceftazidime [6, 9] . TEM, SHV, and CTX-M are the major genetic groups of ESBLs amongst clinically important Gram-negative bacteria [9, 10] . These enzymes are most commonly found in Klebsiella pneumoniae (K. pneumoniae) and Escherichia coli (E. coli) and are also observed in other clinical isolates of Enterobacteriaceae and Pseudomonas [11, 12] . The first TEM-type β-lactamase, produced by a clinical E. coli strain, was reported in 1965. The TEM-type ESBLs are derivatives of TEM-1 and TEM-2 [9] . The SHV-type ESBLs may be found in clinical isolates more frequently than any other types of ESBLs and have been reported from several countries in Europe, such as Austria, France, Italy, and Greece, as well as in the United States and Australia [6, 9, 10] . The CTX-M-type ESBLs developed from TEM and SHV and can be divided into five subgroups according to their amino acid sequence simi-larities, including CTX-M-I, CTX-M-II, CTX-M-III, CTX-M-IV, and CTX-M-V [13, 14] . Detection of ESBLs is important for the surveillance and epidemiological studies of their transmission in medical settings [15] . One major concern regarding the spread of ESBL-producing P. aeruginosa within hospital settings is the treatment failure to infections caused by this organism due to the limitations in therapeutic choices [9, 16] . There are few reports describing the prevalence of TEM-or SHVtype ESBLs in P. aeruginosa in Iran. The aims of this study were to determine the prevalence of ESBLs and to detect the bla TEM , bla SHV and bla CTX-M -types ESBL genes among clinical isolates of P. aeruginosa collected from hospitals of Tehran and Qazvin, two central provinces of Iran.
Methods

Bacterial isolates
The clinical isolates of P. aeruginosa (one isolate per patient) were collected from hospitalized patients of Tehran and Qazvin provinces from March 2013 to December 2014. The bacterial isolates were collected from different clinical specimens, including urine, wounds, sputum, broncoalveolar lavage (BAL), trachea, and blood. These isolates were obtained from patients admitted to intensive care units (ICUs), internal medicine, general surgery, neurology, neurosurgery, and infectious disease wards. Specimens of these patients were sent to the microbiology laboratory of the hospitals under study. The study was approved by the ethics committee of Qazvin University of Medical Sciences (code IR.QUMS. REC.1394.147). Written informed consent was obtained from all subjects enrolled in this study. All isolates were identified as P. aeruginosa using standard microbiological and biochemical tests [17] . The isolates were stored at -70°C in trypticase soy broth (TSB) containing 20% glycerol and subcultured twice prior to testing.
ESBL screening
All isolates were initially screened for ESBLs production using the standard disc diffusion method, using ceftazidime (30µg), cefotaxime (30µg), ceftriaxone (30µg), cefpodoxim (30µg), and aztreonam (30µg). Isolates which were non-susceptible to any of third generation cephalosporins were selected for ESBLs detection phenotypically. The antibiotic disks were purchased from Mast (Mast Diagnostics Group Ltd). P. aeruginosa ATCC 27853 was used as a control strain in antimicrobial suscpetibility testings.
Confirmation of ESBL production
Phenotypic confirmatory tests [18] , which were designed for detecting ESBLs in K. pneumoniae and E. coli, were also performed by comparing the inhibition zone of disks containing cefotaxime or ceftazidime with and without clavulanic acid. E. coli ATCC 25922, E. coli ATCC 35218 and K. pneumoniae ATCC 700603 were used as the quality control strains in antimicrobial susceptibility testing.
Molecular detection of ESBL-encoding genes
ESBL-producing isolates were subjected to Polymerase Chain Reaction (PCR) targeting bla TEM , bla SHV , bla CTX-
, and bla CTX-M-25 genes using the specific primers listed in Table I . Plasmid DNA was extracted using plasmid mini extraction kit (Bioneer Company, Korea). The PCR amplifications were performed in a thermocycler (Applied Biosystems, USA) as follows: 96º C for 5 min and 35 cycles of 1 min at 96º C, 1 min at a specific temperature for each primer and 1 min at 72º C and a final extension step of 10 min at 72º C. Amplification reactions were prepared in a total volume of 25 μl (24 μl of PCR master mix plus 1 μl of Tab. I. Primers used in this study for detecting ESBL-encoding genes.
Targets
Primer One hundred and twenty-five (47%) were male and 141 (53%) were female. Out of the 266 P. aeroginosa isolates, 262 (98.5%) isolates were non-susceptible to at least one of the antibiotics used in the screening test and, among these, 75 (28.6%) isolates were identified as potential ESBL producers using combined disk method. Fifty-nine (78.7%) of ESBL-producing isolates were found to be multidrug-resistant (MDR), i.e. showed intermediate or fully resistance to at least three different classes of antimicrobial agents including β-lactams, aminoglycosides, and fluoroquinolones. Amikacin (58.7%) and piperacillin-tazobactam (53.3%) showed the highest rates of susceptibility among antimicrobials tested in this study, respectively (Table II) . Further, 41 (54.7%) and 40 (53.5%) ESBL-producing isolates were fully or intermediate resistant to meropenem and imipenem, respectively. ESBL-producing isolates were mainly recovered from urine (30.2%), followed by wound (28.3%) samples. The patients affected were mainly those admitted in ICU (54.7%) and the internal wards (45.1%), respectively (Table III) . Of the 75 P. aeruginosa isolates with ESBL phenotype, bla TEM-1 (20-26.7%) was the most common gene, followed by bla CTX-M-15 (13-17.3%), bla SHV-1 (5-6.7%), and bla SHV-12 (3-4%), either alone or in combination (Table IV) . In this study, isolates were, instead, negative for bla CTX-M-2 , bla CTX-M-8 , and bla CTX-M-9 -group genes, as well as for bla CTX-M-25 .
Discussion
P. aeruginosa has recently emerged as a major cause of healthcare-associated infections, especially in immunocompromised people and burn patients [22, 23] .
The treatment of P. aeruginosa infections is increasingly Tab. II. Antimicrobial susceptibility of ESBL-producing P. aeruginosa isolated from hospitals of Qazvin and Tehran (n = 75). complicated due to both intrinsic and acquired resistance to the most commonly prescribed antibiotics in hospital settings [2, 24] . The emergence of ESBL has become a matter of serious concern for the treatment of patients in Iran. ESBL detection is not routinely tested in most laboratories in Iran. There are only few reports on prevalence of ESBL among P. aeruginosa isolates in our country. In the present study, 262 (98.5%) P. aeruginosa isolates were non-susceptible to at least one of the antibiotics used in the ESBL screening test and, among these, 75 (28.6%) isolates were ESBL positive. The prevalence rate of ESBL in our study is lower than the rate reported by Mirsalehian et [32, 33] . Our findings demonstrated that amikacin (58.7%) and piperacillin-tazobactam (53.3%) showed the highest rates of susceptibility among the antimicrobials tested, whereas cefotaxime and ceftriaxone revealed low suscepibility rates of 6.7% and 13.3%, respectively. The inappropriate management of infections through unnecessary and widespread administration of antibacterial agents is likely to be the main predisposing factor leading to the emergence of resistant bacteria in our medical centers. Moreover, the high resistance rate of ESBLs found among the isolates in this study emphasizes the need for a local and national antimicrobial resistance surveillance system for monitoring the administration of antimicrobials in our hospital settings.
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It should be noted that, in this study, 71.5% of extended spectrum cephalosporin non-susceptible isolates were ESBL negative, which can be associated with other resistance mechanisms such as overproduction of chromosomal cephalosporinase (AmpC), up-regulation of efflux systems or decreased outer-membrane permeability. Additionally, our data showed that 54.7% and 53.5% of ESBL-producing isolates were non-susceptible to meropenem and imipenem, respectively. Since in hospital setting the appropriate treatment of infections caused by MDR Gram-negative bacteria is generally achieved by the administration of carbapenems, this finding indicated that the available therapeutic choices are currently limited. This has a relevant clinical impact, especially in the future in case these strains should become more prevalent. This study, in line with previous studies [34, 35] , showed that ESBL-producing isolates were mostly collected from the patients admitted to ICUs. It seems that prolonged period of ICU stay, exposure to broad spectrum antibiotics, chronic underlying conditions, and the use of invasive techniques and devices predispose patients to infection caused by these resistant isolates. 
Conclusions
Findings of the our study show a high prevalence of ES-BL-producing P. aeruginosa isolates carrying bla CTX-M-15 and bla SHV-12 genes in Iran. The presence of ESBL-producing bacteria within the healthcare setting in Iran should be considered a public health concern both therapeutically and epidemiologically. As such, the identification, treatment, and infection control and management of patients infected with these organisms is of prime necessity.
